Depression, Epilepsy, Temporal Lobe
Conditions
Keywords
Cognitive Behavioral Therapy, Selective serotonin reuptake inhibitor, depression, epilepsy
Brief summary
The aim of the study is to compare the effect of group-cognitive-behavioral therapy (CBT)versus treatment as usual with the selective serotonin reuptake inhibitor sertraline, in patients with diagnosis of temporal lobe epilepsy (TLE) and depressive disorder.
Detailed description
patients with temporal lobe epilepsy and depression will be enrolled into one of two treatment modality. The first group will receive 12 group cognitive behavioral sessions. CBT is a psychotherapy focused on the recognition and change of distorted thoughts and maladaptive behaviors. The second group will receive treatment with the selective serotonin reuptake inhibitor sertraline or citalopram for 12 weeks. This antidepressant is wide used to treat depression in patients with TLE.
Interventions
OTHERCognitive behavioral therapy
The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy. The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention
DRUGSSRI
Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned.
Sponsors
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* With Major depressive disorder according to criteria from the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) * Diagnosed with TLE according to the criteria of the International League Against Epilepsy * Literates had sign an informed consent * Patients on antidepressant treatments will be allowed to participate only if they had been at stable doses for more than 8 weeks and still show signs of significant depression
Exclusion criteria
* Patients with high risk of suicide who required hospitalization * Patients who abused or are dependent on drugs * Those with a history of head trauma six months prior to the interview * Patients who have any condition that would prevent them from understanding the study or the psychotherapeutic process, such as mental retardation, psychosis, delirium, dementia, etc * Patients who have previously received CBT * Patients who have started, an antidepressant drug the last 8 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Beck Depression Inventory score | baseline, 6 weeks and 12 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life in Epilepsy Scale | baseline, 6 weeks and 12 weeks | the quality of life in epilepsy scale measures the patients perceived quality of life. Higher score indicates better quality of life. score goes from 0 to 100 |
| Hospital anxiety and depression scale (HADS) | baseline, 4weeks and 12 weeks | the HADS measures severity of symptoms of anxiety and depression. Lower scores indicates less symptoms |
Countries
Mexico
Outcome results
None listed